At NINGBO INNO PHARMCHEM CO.,LTD., we understand the intricate relationships between drugs and their active metabolites. Today, we explore SN-38, the active metabolite of Irinotecan, and its pivotal role in cancer therapy, highlighting its chemical identity as 7-Ethylcamptothecin (CAS 78287-27-1).

SN-38 is synthesized in the body from Irinotecan (CPT-11) through enzymatic conversion. It is significantly more potent than its prodrug, demonstrating a much higher affinity for topoisomerase I. This enhanced activity is key to its efficacy in inhibiting cancer cell growth and survival. The extensive research into the 7-Ethylcamptothecin synthesis and antitumor activity is largely driven by the understanding of SN-38's potent effects.

The 7-ethyl-10-hydroxycamptothecin mechanism of action involves stabilizing the DNA-topoisomerase I complex, preventing DNA religation and leading to lethal DNA breaks during replication. This powerful cytotoxic effect makes it a prime target for drug development. Researchers often seek to buy 7-Ethylcamptothecin online to study these mechanisms and to develop formulations that improve SN-38's bioavailability and stability.

While SN-38 itself faces challenges with solubility and rapid inactivation at physiological pH, its potent activity underscores the importance of Irinotecan in chemotherapy. Ongoing research, supported by reliable suppliers like NINGBO INNO PHARMCHEM CO.,LTD., aims to overcome these limitations, potentially through novel drug delivery systems. This ensures that the powerful therapeutic potential of SN-38, as represented by 7-Ethylcamptothecin, can be fully harnessed for improved cancer treatment outcomes.